跳至主要内容
临床试验/NL-OMON44810
NL-OMON44810已完成4 期

Quadrivalent HPV vaccination after effective treatment of Anal Intraepithelial Neoplasia in HIV+ men (VACCAIN-P) - HPV vaccination after treatment of anal intraepithelial neoplasia

Academisch Medisch Centrum0 个研究点目标入组 125 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
125

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Written informed consent
  • HIV+ males having sex with males (MSM), CD4 count > 350/ul.
  • Biopsy-proven intra-anal high-grade AIN successfully treated in the past year with cauterization, cryotherapy, Efudix, imiquimod or another form of local treatment. Lesions with regression from HG to Low grade (LG) AIN will also be eligible.
  • Lesion (still) in remission at the moment of first vaccination (a maximum interval of 6 weeks between last HRA and first vaccination is allowed).
  • Good performance status (a Karnofsky performance score of >= 60 [on a scale of 0 to 100, with higher scores indicating better performance status])
  • Normal pretreatment laboratory blood values

排除标准

  • Immunosuppressive medication or other diseases associated with immunodeficiency
  • Life expectancy less than one year
  • Previous vaccination with the bivalent or quadrivalent HPV vaccine
  • History of anal carcinoma

研究者

相似试验